Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

June 18, 2008 09:05 ET

Osta Reports Significantly Enhanced Anti-Metastatic Activity of its New Experimental Drug for Prostate Cancer

MONTREAL, QUEBEC--(Marketwire - June 18, 2008) - THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.

Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced promising results of a pre-clinical efficacy optimization study on its lead anti-cancer therapeutic agent OB-24, in a highly aggressive & metastatic human prostate cancer model. Data from this study showed that the combination of OB-24 and taxol greatly potentiated taxol's anti-tumor activity and completely prevented the formation of both macroscopic and microscopic lymph node metastases. The data highlights the enormous potential of OB-24 as a highly effective anti-cancer drug, which either alone or in combination with other chemotherapeutic agents such as taxol, could become an effective new approach for the treatment of metastatic, androgen-refractory and chemotherapy resistant human prostate cancer.

The study was conducted in an androgen independent metastatic human prostate cancer pre-clinical model. The highly metastatic and aggressive human prostate carcinoma PC-3M cells were implanted into the mouse prostate to mimic the actual tumor micro-environment as it occurs in humans. Data from this pre-clinical study showed statistically significant reduction in the tumor volumes in mice treated with OB-24 via intravenous injections compared to untreated mice. Multiple intravenous (i.v.) injections of OB-24 at 30mg/kg were well tolerated with no apparent toxicity. The activity of i.v. OB-24 at 30 mg/kg dose was higher than the same dose given intraperitonially (i.p.). Data from this study demonstrate the therapeutic bioavailability of OB-24 when administered i.v. and confirm the findings of a previous study that was made public on March 11, 2008, which showed a statistically significant reduction in prostate tumor weights in mice treated with OB-24 compared to untreated mice, a comparable reduction in tumor weights in mice treated with taxol and OB-24, and a significant synergistic effect when OB-24 was combined with taxol.

Dr. Ajay Gupta, Chairman & CEO of Osta commented "We are quite excited with these results as our lead anti-cancer drug OB-24, is continuing to show consistent promise as a novel class of a powerful anti-cancer and anti-metastatic drug, especially when used in combination with the standard of care drugs such as taxol. We are continuing to optimize the route of administration of OB-24 in aggressive and metastatic prostate cancer models. The successful development of OB-24 either alone or in combination with existing chemotherapy drugs for the treatment of androgen-refractory and chemotherapy resistant human prostate cancer, would represent a major breakthrough in the treatment of this devastating disease."

Results of the Pre-Clinical Study

The pre-clinical study was conducted in collaboration with Dr. M. Alaoui-Jamali, a Professor of Oncology & Senior Scientist at McGill University and the Leader of Drug Discovery Group at the Segal Cancer Centre of the Jewish General Hospital. In a pre-clinical study involving a total of 48 Scid male mice implanted with human metastatic prostate cancer PC-3M cells in the mouse prostate, the tumor volumes were found to be statistically significantly smaller in mice treated i.v. with OB-24 at 30 mg/kg daily for 12 days (58% inhibition) compared to untreated mice and compared to mice treated i.p. with OB-24 at 30 mg/kg daily for 12 days (34%). Remarkably, OB-24 at 30 mg/kg given i.p. daily for 12 days in combination with taxol at 10 mg/kg administered i.p. for 3 cycles (3 days per cycle), led to a 86% inhibition in tumor growth a compared to the mice treated with taxol alone (64%). Also, OB-24 at 30 mg/kg given i.v. daily for 12 days in combination with taxol at 10 mg/kg administered i.p. for 3 cycles (3 days per cycle), led to a 94% inhibition in tumor growth compared to the mice treated with taxol alone (64%). In addition, there was a complete inhibition in the formation of both macroscopic and microscopic lymph node metasteses in mice treated with OB-24 at 30 mg/kg given i.p. or i.v. daily for 12 days in combination with taxol at 10 mg/kg administered i.p. for 3 cycles (3 days per cycle), compared to a 82% reduction in microscopic lymph node metastases in mice treated with taxol alone at 10 mg/kg administered i.p. for 3 cycles (3 days per cycle). The reduction in microscopic lymph node metastases in mice treated with OB-24 alone at 30 mg/kg given i.p. daily for 12 days was 59% compared to a reduction of 76% in microscopic lymph node metastases in mice treated with OB-24 alone at 30 mg/kg given i.v. daily for 12 days. These results clearly indicate that OB-24 synergizes with taxol by making this major chemotherapeutic agent significantly more effective.

Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSXV: OBI) dedicated to developing novel diagnostics and therapeutics for the aging population particularly in the areas of Cancer, Alzheimer's disease, Osteoporosis, Osteoarthritis and XLH.

Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Mr. Alain Geahchan
    Director of Operations
    514-567-5505
    or
    Osta Biotechnologies Inc.
    Dr. Ajay Gupta
    Chairman & CEO
    514-626-0322